Literature DB >> 8615659

The expression of myc and ras oncogene protein in childhood lymphomas.

A Sakalidou1, P Kanavaros, M Tzardi, M Kalmanti.   

Abstract

Paraffin sections from 21 cases of Hodgkin's disease (HD), 18 cases of non-Hodgkin's lymphomas (NHL) and 15 cases of reactive lymphadenitides occurring in children 3-15 years old were examined by immunohistochemistry for the presence of c-myc and pan-ras oncogene products. In all cases of childhood lymphomas studied c-myc protein was expressed. The highest percentage was in HD where in 29% of cases the percentage of positive cells was greater than 20%, while in only 6% of NHL cases this percentage was noted. In all cases of reactive lymphadenitides the number of cells where c-myc was expressed was less than 5%. The ras oncogene was also found in HD but with a lesser degree of positivity than c-myc. In 48% of these cases the number of positive cells ranged between 2 and 10%, while in NHL and in reactive lymphadenitides there was no positivity. The above results indicate a frequent expression of c-myc protein in childhood lymphomas. This could reflect either an implication of c-myc oncogene in the pathogenesis of these tumor or an epiphenomenon of lymphomagenesis reflecting the proliferation rate of tumor cell population. Molecular biology studies are needed to clarify this issue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615659

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.

Authors:  C Fenton; J Anderson; Y Lukes; C A Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.

Authors:  Elizabeth A Raetz; Sherrie L Perkins; Marlee A Carlson; Kevin P Schooler; William L Carroll; David M Virshup
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.